GSK gets first approval for two-drug HIV treatment

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Anghi)
(Image: Getty/Anghi)

Related tags: Gsk, Hiv, Aids, Gilead

GSK’s Dovato is approved by the US FDA for the treatment of individuals with HIV with no previous antiretroviral therapy, in a first for a two-drug, fixed-dose, complete regimen.

The two-drug combination comes in one pill, meaning that patients are able to take one tablet daily to manage the HIV infection.

In clinical trials, Dovato, comprised of dolutegravir 50mg and lamivudine 300mg, proved non-inferiority compared to a three-drug regimen of dolutegravir and tenofovir disoproxil fumarate/emtricitabine, in treatment naïve patients.

Pedro Cahn, principal investigator for the clinical trial program, said, “Treatment-naïve people living with the virus have a powerful option that delivers non-inferior efficacy to a dolutegravir-based three-drug regimen, allowing them to take fewer ARVs and get and remain suppressed.”

The treatment is currently under review by the European Medicines Agency, as well as regulatory authorities in Canada, Australia, Switzerland, and South Africa.

Current standards of care see patients take combination therapies of three drugs; this includes a rival in the space, Gilead, which possesses the recently approved anti-retroviral drug​ (ARV), Biktary (bictegravir, emtricitabine, and tenofovir alafenamide).

Dovato medicine. ViiV Healthcare.

According to GSK, which will commercialise the drug under its ViiV Healthcare subsidiary, the advantage of its two-drug treatment is reduced exposure to ARVs, with patients avoiding the additional side effects that arrive with additional drugs.

Jeff Barry, of the Test Positive Aware Network, suggested that reducing the number of drugs involved in the therapy for patients adhering to the treatment could “help address concerns arising from overall management of prolonged ARV therapy.”

Dovato is the second treatment that GSK has brought to market that uses a two-drug formulation to suppress the HIV virus, with Juluca (dolutegravir and rilpivirine) also being approved but for patients that have previously received treatment.

The WHO estimates that there are 36.9 million cases of HIV and AIDS worldwide – a population size that saw GlobalData suggest​ that the market for supplying therapies could be worth $22.5bn (€19.9bn) by 2025.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us


View more